Tepawel Injection (15mg), which contains the active ingredient Thiotepa, is a potent chemotherapeutic agent primarily used in the treatment of various cancers, including breast cancer, ovarian cancer, and bladder cancer. This medication works by interfering with the growth and spread of cancer cells in the body. Tepawel Injection is typically administered intravenously, allowing for direct delivery into the bloodstream, which enhances its efficacy. The composition of Tepawel includes Thiotepa, a nitrogen mustard derivative, which is known for its alkylating properties that damage the DNA of rapidly dividing cells, leading to cell death. This drug is often utilized in combination with other chemotherapy agents to improve treatment outcomes. Patients receiving Tepawel Injection are closely monitored for side effects and therapeutic response, making it a critical component in the oncology treatment landscape.

Thiother Injection (15mg), which contains the active ingredient Thiotepa, is a potent chemotherapeutic agent primarily used in the treatment of various cancers, including breast cancer, ovarian cancer, and bladder cancer. Thiotepa functions as an alkylating agent, disrupting the DNA synthesis of rapidly dividing cancer cells, thereby inhibiting tumor growth. The injection is typically administered intravenously and is formulated to ensure precise dosing and effective delivery of the medication into the bloodstream. Thiother Injection is often utilized in combination with other chemotherapy drugs to enhance its efficacy and improve patient outcomes. As a critical component of cancer treatment regimens, Thiother Injection plays a vital role in managing malignancies and improving the quality of life for patients undergoing cancer therapy.